Schrodinger Inc Revenue Growth Rates (SDGR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Schrodinger Inc   (NASDAQ: SDGR)
 

SDGR's Revenue Growth by Quarter and Year

Schrodinger Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SDGR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 58.89
1st Quarter March 58.59
FY 117.48

SDGRs Annual Revenue
Schrodinger Inc 's Revenue in the fiscal year 2025 $ 255.87 millions
Schrodinger Inc 's Revenue in the fiscal year 2024 $ 207.54 millions
Schrodinger Inc 's Revenue in the fiscal year 2023 $ 215.69 millions
Schrodinger Inc 's Revenue in the fiscal year 2022 $ 180.96 millions
Schrodinger Inc 's Revenue in the fiscal year 2021 $ 137.93 millions




SDGR Revenue second quarter 2026 Y/Y Growth Comment
Schrodinger Inc reported Revenue growth of 7.54% year on year in the second quarter 2026, to $ 58.89 millions, this is lower than Schrodinger Inc 's recent average Revenue improvement of 20.08%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 104 other companies have achieved higher Revenue growth. While Schrodinger Inc ' s Revenue increase of 7.54% ranks overall at the positon no. 2231 in the second quarter 2026.


SDGR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -3.71 % 22.29 % 30.33 %
3rd Quarter September - 56.41 % -16.59 % 12.6 %
2nd Quarter June 7.54 % 18.17 % 31.69 % -8.53 %
1st Quarter March -1.61 % 65.92 % -44.6 % 33.13 %
FY   - 23.28 % -3.77 % -

Financial Statements
Schrodinger Inc 's second quarter 2026 Revenue $ 58.89 millions SDGR's Income Statement
Schrodinger Inc 's second quarter 2025 Revenue $ 54.76 millions Quarterly SDGR's Income Statement


SDGR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 60.59 % 160.84 % 77.91 %
3rd Quarter September - -0.8 % -25.05 % 18.33 %
2nd Quarter June 0.51 % -8.04 % 29.12 % -45.68 %
1st Quarter March -32.83 % -34.26 % -51.55 % 13.97 %
FY (Year on Year)   - 23.28 % -3.77 % -


Back to SDGR Growth rate Comparisons >> Back to SDGR Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #105
Healthcare Sector #326
Overall #2231

Revenue Y/Y Growth Statistics
High Average Low
36.45 % 20.08 % -5.21 %
(Sep 30 2022)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #105
Healthcare Sector #326
Overall #2231
Revenue Y/Y Growth Statistics
High Average Low
36.45 % 20.08 % -5.21 %
(Sep 30 2022)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Schrodinger Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
160.84 % 10.26 % -51.55 %
(Dec 31 2024)  


SDGR's II. Quarter Q/Q Revenue Comment
Schrodinger Inc achieved in the II. Quarter 2026 below company average Revenue growth of 0.51% quarter on quarter, to $ 58.89 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -8.04% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Schrodinger Inc 's Revenue growth quarter on quarter, overall rank is 1702.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #226
Overall #1702
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #226
Overall #1702
Revenue Q/Q Growth Statistics
High Average Low
160.84 % 10.26 % -51.55 %
(Dec 31 2024)  


SDGR's II. Quarter Q/Q Revenue Comment
Schrodinger Inc achieved in the II. Quarter 2026 below company average Revenue growth of 0.51% quarter on quarter, to $ 58.89 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -8.04% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue quarter on quarter growth. While Schrodinger Inc 's Revenue growth quarter on quarter, overall rank is 1702.


Schrodinger Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 259.03 $ 254.91 $ 255.87 $ 259.22 $ 239.62
Y / Y Revenue Growth (TTM) 8.1 % 10.25 % 23.29 % 35.69 % 21.06 %
Year on Year Revenue Growth Overall Ranking # 814 # 2615 # 1720 # 1417 # 2618
Seqeuential Revenue Change (TTM) 1.62 % -0.38 % -1.29 % 8.18 % 3.64 %
Seq. Revenue Growth (TTM) Overall Ranking # 2231 # 1239 # 1712 # 1558 # 3015


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Schrodinger Inc 's cumulative twelve months Revenue were $ 259 millions, company would post below average annual Revenue growth of 3.64% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Schrodinger Inc 's Revenue growth from the 58.59% growth in Mar 31 2026.

In the Healthcare sector 169 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 814, from total ranking in previous quarter at 2615.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 170
Overall # 814

Revenue TTM Y/Y Growth Statistics
High Average Low
36.45 %
 20.08 %
-5.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 326
S&P 500 # 2231
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Schrodinger Inc 's cumulative twelve months Revenue were $ 259 millions, company would post below average annual Revenue growth of -5.21% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Schrodinger Inc 's Revenue growth from the 58.59% growth in Mar 31 2026.

In the Healthcare sector 169 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 814, from total ranking in previous quarter at 2615.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 170
Overall # 814

Revenue TTM Y/Y Growth Statistics
High Average Low
36.45 %
20.08 %
-5.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 326
S&P 500 # 2231




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SDGR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions
Gilead Sciences Inc 10.18%$ 10.181 millions
Lifeloc Technologies Inc 10.16%$ 10.163 millions
Abbvie Inc 10.16%$ 10.160 millions
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions


About Schrodinger Inc Revenue Growth Rates (SDGR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Schrodinger Inc (CIK 1490978).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001490978-26-000068
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Schrodinger Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.